(FHTX) – Company Press Releases
-
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
-
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
-
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
-
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
-
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
-
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
-
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-90
-
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
-
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
-
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
-
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
-
Flagship Pioneering Debuts Enabling Technologies Initiative
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
-
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
-
Foghorn Therapeutics Announces CFO Departure
-
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hemat
-
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
-
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
-
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
-
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
-
Flagship Pioneering Launches Pioneering Intelligence
-
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
-
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
-
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
-
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
-
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
-
Flagship Pioneering Named to Fortune's 2023 "Change the World" List
-
ProFound Therapeutics Expands Leadership Team With Appointment of Klaus Urbahns as Chief Scientific Officer
-
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
-
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
-
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
-
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
-
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner
-
Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer
-
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines
-
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
-
Foghorn Therapeutics Announces Chief Medical Officer Succession
-
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
-
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
-
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
-
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
-
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
-
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
-
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
-
Foghorn Therapeutics Provides an Update on FHD-609
-
Foghorn Therapeutics Provides an Update on FHD-609
Back to FHTX Stock Lookup
